MacroGenics Analyst Sees Multiple Sources Of Upside, Biopharma Rallies After Q1 UpdateBenzinga • 05/06/20
MacroGenics' (MGNX) CEO Scott Koenig on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/06/20
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/26/20
MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDAGlobeNewsWire • 12/19/19
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer SymposiumGlobeNewsWire • 12/11/19
MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual MeetingGlobeNewsWire • 12/09/19
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/11/19
MacroGenics Announces Flotetuzumab Presentations at the ASH Annual Meeting 2019GlobeNewsWire • 11/06/19
MacroGenics (MGNX) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/30/19
MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction CancerGlobeNewsWire • 10/25/19